Scan Results
Daily timeframeQiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. With a market capitalization of $6.33B, it sits in mid-cap territory. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories.
Market Cap
$6.33B
Beta
0.64
P/E (TTM)
18.17
P/E (Fwd)
13.63
EPS (TTM)
$1.69
EPS (Fwd)
$2.25
ROE
11.9%
ROA
6.0%
Cash
$646.3M
Total Debt
$1.67B
Free CF
$238.9M
52W Change
-27.4%
Annual Financials
Cash vs Debt
Qiagen N.V. carries $1.67B in total debt against $646.3M in cash reserves — debt is roughly 2.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $238.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 11.9%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.0% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $2.14B (2022) to $2.09B (2025).
With a beta below 0.7, Qiagen N.V. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Qiagen N.V.'s trajectory.